Orthocell (ASX:OCC) said 10 surgeries have taken place in the US using its nerve repair product, Remplir, and it lodged 36 applications to hospital value assessment committees with three approvals already received, according to a Wednesday Australian bourse filing.
The hospitals targeted for value assessment committee approval have been sourced from the firm's network of US distributors.
The company hired two on-the-ground employees in the US, including a regional sales director, per the filing. It also shipped 4,000 Remplir units to its US logistics provider, Uniphar, for use in US surgical procedures.
Orthocell's shares rose nearly 2% in early trading on Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。